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Melanoma is the most fatal type of skin cancer. It is ranked first in death of skin cancer 
diseases. This study establishes a statistical model that can predict the survival time of 
localized melanoma patients, as a function of age at diagnosis, tumor thickness, and 
extension of the tumor (tumor invasion). The discrete time survival method was used to 
build the statistical model. The patients involved in the current study were observed from 
the SEER database. Patients were divided into nine groups according to age at diagnosis. 
Variation in survival time was found to be significant among some of the age groups. 
 
Keywords: melanoma, survival time, discrete survival time, skin cancer, SEER, 
localized melanoma 
 
Introduction 
Melanoma is a malignant tumor associated with skin cancer. If melanoma is 
detected at a late stage, it can spread to other parts of the body and that’s what 
makes it a lethal form of cancer. More general information about melanoma can 
be found in (www.melanoma.org), (Markovic, et al., 2007) and (Mackle, et al., 
2009). Over the last decades, the incidence of melanoma has been rapidly 
increasing in the United States. It appears more in white populations than other 
races. According to clinical studies, risk factors of melanoma are but not limited 
to, ultraviolet light exposure, moles, light hair, freckling and family history of 
melanoma. Some of the statistical analyses done on the risk factors are shown in 
(Gandini, et al., 2005c; Naldi, et al., 2000; Cho, et al., 2005). 
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Consider the survival time for melanoma patients. The primary objective is 
the time between when the patient is diagnosed with melanoma and when death 
occurs. The study includes the effect of three risk factors that drives the survival 
time for a patient. Those risk factors are Age at diagnosis, tumor thickness and 
extension of the tumor (invasion of tumor through the body). Other factors 
include gender and sequence number (a number that indicates how many tumors 
the patient had prior to being diagnosed with melanoma).  The main concern will 
be in estimating the survival time of melanoma patients diagnosed at stage one 
(localized Melanoma). More information regarding staging is discussed in the 
Methodology; for updates on the staging of melanoma visit www.cancer.gov. 
Soong, et al. (2010) developed an electronic prediction tool based on the 
American Joint Committee on Cancer (AJCC) melanoma staging database, to 
predict survival outcome of localized melanoma. Other predictive models of 
survival for localized melanoma have been developed in the United States and 
other countries (Clark, et al., 1989; MacKie, et al., 1995; Barnhill, et al., 1996; 
Schuchter, et al., 1996; Sahin, et al., 1997; Soong, et al., 2003). Soong, et al. 
(2010) used the Cox survival function model, which considers the survival time as 
a continuous random variable, where most survival times are recorded in discrete 
form as a number of months or years. They used same three risk factors in their 
analysis beside the primary melanoma site and primary tumor ulceration. As 
shown in Table 3, there exist 10 primary melanoma sites, and in order to reduce 
the variation in the model (biological variation between humans is a lurking 
variable), only one site of the ten was studied. Allison (1982) mentioned that in 
continuous survival time, maximum likelihood method ignores the discrete 
character of the data. 
Xie, Mchugo, Drake, and Sengupta (2003), summarized the advantages of 
using discrete-time survival analysis. These were initially suggested by Singer & 
Willett (1993) as primarily useful for many longitudinal studies in clinical settings 
where data are often collected at discrete time periods. Secondly, the analysis 
facilitates the examination of the shape of the hazard function. Third, the analysis 
is simple and convenient to use, because it is a modification of the logistic 
regression model. Lastly and most important, time-varying covariates can easily 
be included in the model. After Cox presented the discrete time survival model, 
two basic versions of logistic models were introduced: the ordinal version and the 
dichotomous version. The dichotomous version (Allison, 1982; Singer & Willett, 
1993; Xie, et al., 2003) represents each survival time as a set of indicators of 
whether or not an individual failed at each time point, until a person either 
experiences the event or is censored. 
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Methodology 
Allison (1982) and Singer and Willett (1993) proposed a discrete survival time 
method. The method starts by dividing the continuous time into an infinite 
sequence of contiguous time      1 1 2 10, , , , , , ,k kt t t t t  and so on. Let k 
represent the number of time intervals. In this case, time is recorded in months, 
where time is divided into 20 intervals each consists of 12 months: 
(1,12),(12,24),…,(228,240). If a patient’s survival time is 7 months, then this 
patient’s event is classified as happening during the 1st time interval; if another 
patient’s survival time is 50 months, then this is classified as happening during the 
5th time interval. 
To estimate the survival function, start with the discrete-time hazard model 
(Allison, 1982) 
 
 
    1 1 2 2 1 1 2 2
1
1
ik
ik ik J Jik ik ik p pik
h
EXP T T T X X X     

        
 
 (1) 
 
where  1 2, , ,ik ik J JikT T T  are a sequence of dummy variables, with values 
 1 2, , ,ik ik Jikt t t  indexing time periods, where J refers to the last time period 
observed for any individual in the sample. If individual 𝑖  was observed 
(experienced the event or censored) in the fourth period, then J = 4, and the time 
period’s dummy variables are defined identically for each individual;  t1ik =1 
when j = 1 and 0 when j takes any other value.  
The coefficients  1 2 J    act as the intercept parameters for the baseline 
hazard in each time period, and the coefficients  1 2 p    describe the effect of 
the predictors on the baseline hazard in the logit scale. Singer and Willett (1993) 
discussed briefly the procedures to construct the likelihood function (in terms of 
the discrete hazard function) used to estimates the latter intercepts and slope 
parameters. 
The likelihood function presented by Singer and Willett (1993) is given by 
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where 
 
y
ik
 is a sequence of dummy variables that records the event history for 
patient 𝑖, whose values are defined as: 
 
yik = { 1 if the ith patient experienced the event in period k 0 if the ith patient did not experience the event in period k 
 
The likelihood function is identical to the likelihood function to a sequence 
of  1 2 nN k k k     independent Bernoulli trials with parameters ikh . 
Using results by Allison (1982), the 
iky  values can be considered as the 
outcome variable in a logistic regression analysis, which provides a simple model 
to obtain the maximum likelihood estimate rather than finding the solution by 
maximizing equation (2). 
For discrete event history data, each record consists of the information for 
one patient like survival time, Age and whether or not the patient time is censored 
or not. In order to apply the logistic model discussed previously, the data need to 
be converted into new person-period data, in which each patient will have 
multiple records, one per time period of observation. As shown by Singer and 
Willett (1993), the new person-period data will contain the information about the 
kth time period as follows 
 
 The time indicators. The set of dummy variables  1 2, , ,ik ik J JikT T T . 
 The predictors. Covariates under study, where the ability exists to use 
the time-varying covariates that have values differs from time period 
to time period. 
 The event indicator (response variable in the logistic model). This 
variable records whether the event of interest occurred in period j or 
not. The variable takes value 1 if the event occurred, takes 0 if did not. 
 
In this study, the survival time of melanoma patients diagnosed in the period 
of 1988 to 2008 was considered. The survival time was recorded up to the nearest 
month. The time period of the study was divided into 20 intervals, one year each. 
Besides the covariates age at diagnosis, tumor size and extension of the tumor, 
there were 20 dummy variables representing the 20 time periods as shown in 
Tables 1 and 2. In Table 1, there is a record of 3 patients as extracted from 
Surveillance Epidemiology and End Results database (SEER) database. In Table 
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2, there is a representation of the conversion of the data to fit the new person-
period data to be used for the logistic model. 
 
 
Table 1. A record of 3 patients from SEER database. 
 
Patient ID Survival Time (mos) Age Diagnosis Tumor Size Extension of Tumor 
7013574 49 84 120 10 
8862253 3 66 230 30 
8869492 86 61 134 30 
 
 
Table 1 shows that the first patient survival time is 49 months. The first 
patient lived for four years and died in the first month of the fifth year, which 
means that the event took place during the fifth time period. In the new data 
setting the first patient will have five records, one record corresponding to every 
time period (from the first to the fifth). The event indicator variable will take 0 for 
the first four records and 1 in the fifth record where the event took place. Table 2 
shows this conversion for the three patients in table one. 
 
 
Table 2. A sample of three patients from the new person-period data. 
 
Indc. ID ST A TS D1 D2 D3 D4 D5 D6 D7 D8 …  D20 
0 1 49 84 120 1 0 0 0 0 0 0 0 … 0 
0 1 49 84 120 0 1 0 0 0 0 0 0 … 0 
0 1 49 84 120 0 0 1 0 0 0 0 0 … 0 
0 1 49 84 120 0 0 0 1 0 0 0 0 … 0 
1 1 49 84 120 0 0 0 0 1 0 0 0 … 0 
1 2 3 66 230 1 0 0 0 0 0 0 0 … 0 
0 3 86 61 134 1 0 0 0 0 0 0 0 … 0 
0 3 86 61 134 0 1 0 0 0 0 0 0 … 0 
0 3 86 61 134 0 0 1 0 0 0 0 0 … 0 
0 3 86 61 134 0 0 0 1 0 0 0 0 … 0 
0 3 86 61 134 0 0 0 0 1 0 0 0 … 0 
0 3 86 61 134 0 0 0 0 0 1 0 0 … 0 
0 3 86 61 134 0 0 0 0 0 0 1 0 … 0 
1 3 86 61 134 0 0 0 0 0 0 0 1 … 0 
 
 
The variables 1 2 20, , ,D D D  represent the 20 dummy variables for the time 
intervals. Each row shows patient 𝑖 information during each time interval until the 
event occurs or he/she is censored. The first column in Table 2 (Indc.) represents 
the indicator variable, which takes 0 if the event did not take place during the 
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current time period interval, or 1 if the event occurs during the time period 
interval. The patient’s ID was changed to ID (1, 2 and 3) to optimize the table. 
The setting of the data shown in Table 2 can allow us to use time varying 
covariates easily, but because the data used does not support this information the 
covariates were repeated. Only the tumor size of the patient is known at the time 
of diagnosis; no follow up information was supported. Age at diagnosis can be 
changed, but no big difference will appear (as will be shown); ages were grouped 
into 9 intervals, each interval covering 10 years. 
The data set used was collected from the Surveillance Epidemiology and 
End Results database (SEER) 1973-2008. 208,143 patients were diagnosed in the 
United States from 1973 through 2008. Taking into account the patients that were 
confirmed dead because of melanoma cancer, and removing all the missing 
records in the covariates shown in Table 4, results in studying the patients 
diagnosed from 1988 through 2008. Melanoma cancer is classified into 4 stages 
as shown in Table 3, and there exist 10 sites of the skin where the cancer appears. 
In order to reduce the variation (biological difference between humans) and to get 
less prediction error in the statistical model, only ‘skin of trunk’ patients in stage 
1 (localized melanoma) are considered in this study. The sample size used in this 
study is 1,240. Table 3 shows the description of the coding used for the primary 
site and the staging of the cancer. 
The risk factors (affecting the survival time of patients) that were involved 
in the study are age of the patient, the tumor size and the tumor extension (how 
far the tumor spread). Around 99 percent of the 1,240 patients were white (due to 
the fact that melanoma is rare in people with dark skin), which is why race was 
not considered in the modeling aspects. 
Age of patients at Diagnosis was classified into 9 groups, 10 years each, 
starting from 11 to 20 years in the first group through 91 to 100 years old. Tumor 
thickness (instead of size as known in other cancer types, the thickness is 
measured, but size will be referred to for the remainder of this article) was 
classified into 3 groups, the first group from 1mm to 50mm, the second group 
from 51mm to 300mm and the last group from 301mm to 992mm. In the current 
sample the extension of the tumor contains 4 levels which are as stated in SEER 
EOD-88 3rd edition; (10) for papillary dermis (the middle layer of skin) invaded, 
(20) for papillary-reticular dermal interface invaded, (30) for reticular dermis 
invaded and finally (40) localized. A summary of the number of patients lying in 
the groups stated previously is shown in Table 4. 
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Table 3. SEER coding for the stage and primary site for Melanoma. 
 
Variable Code Description 
SEER Historic 
stage 
0 In situ : A tumor which has not penetrated the basement membrane nor extended beyond the epithelial issue 
1 Localized : An invasive neoplasm confined entirely to the organ of origin 
2 Regional: A neoplasm that has gone beyond the bounds of the organ of origin or into regional lymph nodes. 
4 Distant : A neoplasm that has spread to parts of the body distant from the primary tumor 
Primary Site 
C440 Skin of lip 
C441 Eyelid 
C442 External Ear 
C443 Skin of other and unspecified parts of face 
C444 Skin of Scalp and neck 
C445 Skin of Trunk 
C446 Skin of upper limb and shoulder 
C447 Skin of lower limp and hip 
C448 Overlapping lesion of skin 
C449 Skin NOS 
 
 
Table 4 illustrates that around 46.5% of the patients are diagnosed at the 
third level of tumor extension where the tumor invaded into the reticular dermis, 
indicating that there is a delay from patients until they figured out that they 
needed medical attention. It must be stressed that during the current study no 
treatment effects were added to the statistical model, so study results are 
considered as if patients did not get any treatment. The different treatment effects 
and histology effects will be studied in further publications. 
Descriptive statistics of the survival time of melanoma patients recorded in 
months from time of diagnosis till death for each age group are recorded in Table 
5. Because the survival time distribution is skewed, it is important to estimate the 
median survival time for the melanoma patients. The median will be more 
informative than the mean in this case. The large variance of survival time inside 
each group can be seen. This assures the presence of independent variables 
affecting the survival time. 
  
SHARAF & TSOKOS 
147 
Table 4. Distribution of the 1240 patients on the various groups. 
 
Factor  Extension of the Tumor    
Age Tumor Size   10 20 30 40   Total % 
11-20 
1        
0.4838710 2  1 4    5 
3     1  1 
21-30 
1  3 10 2 1  16 
4.2741935 2  3 11 12 4  30 
3    6 1  7 
31-40 
1  8 3 11 3  25 
13.3870970 2  11 52 50 8  121 
3   5 15   20 
41-50 
1  14 9 13 2  38 
20.3225810 2  10 87 73 12  182 
3   8 20 4  32 
51-60 
1  17 9 19 7  52 
20.3225810 2  17 61 73 14  165 
3   3 27 5  35 
61-70 
1  14 3 11 5  33 
20.4032260 2  14 59 87 18  178 
3   4 33 5  42 
71-80 
1  18 7 12 4  41 
15.2419350 2  8 36 60 15  119 
3   7 19 3  29 
81-90 
1  6 2 11 3  22 
5.0806452 2  3 9 14 5  31 
3   3 5 2  10 
91-100 
1  1  1   2 
0.4838710 2   1 2   3 
3    1   1 
%     11.94000 31.69000 46.53000 9.83871   1240 100% 
 
 
Table 5. Descriptive statistics of survival time. 
 
 Survival Time 
Age Count Mean Median St. deviation  Skewness 
11-20 6 74.50 57.00 42.43 1.39 
21-30 53 61.40 46.00 44.10 1.11 
31-40 166 66.95 52.50 48.48 1.21 
41-50 252 67.83 55.50 45.53 1.15 
51-60 252 56.90 43.00 41.17 1.32 
61-70 253 53.96 41.00 42.11 1.58 
71-80 189 50.38 45.00 32.86 0.89 
81-90 63 38.44 34.00 28.05 1.26 
91-100 6 32.17 26.00 31.92 1.91 
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Results 
Three out of the four models proposed models are discussed. The first model is 
the baseline model, estimating the survival function using the time periods. The 
second model introduces age at diagnosis as the first covariate with the time 
periods. The third model uses age at diagnosis and tumor size as covariates with 
the time periods. The fourth model introduces all three covariates with the time 
periods. 
Model 1 
The baseline model is the starting point of the proposed modeling procedure. The 
simplest hazard model from equation (1), considering only the 20 dummy 
variables that represent the time effect, is considered. The baseline hazard model 
for this case is represented as: 
 
 1 1 2 2 20 20( ) ( )ilogit h t t t        (3) 
 
Equation (3) represents the log transform of equation (1), where 
 
 ( ) log
1
ik
ik
ik
h
logit h
h
 
  
 
  (4) 
 
This model will answer the basic question ‘what is the probability of obtaining the 
event (melanoma patient dies due to the cancer) in each time period?’ In other 
words what is the probability that a melanoma patient will survive for one, or two 
years, etc. 
The parameters in equation (3) can be converted by exponentiation the right 
hand side. For example if it is desired to know the estimate of the probability of 
event occurrence in the fifth interval will be equal to 
 
 
55
1ˆ
(1 )
h
e



  (5) 
 
The estimates of the baseline hazard are presented in Table 6. After 
estimating the baseline hazard one can calculate the corresponding survival 
function using 
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1
ˆˆ (1 )
k
k j
j
S h

    (6) 
 
 
Table 6. Estimates of the baseline hazard parameters. 
 
Param. ˆ    Param. ˆ   
D1 -2.687  D11 -0.743 
D2 -1.642  D12 -1.326 
D3 -1.372  D13 -1.017 
D4 -1.242  D14 -0.758 
D5 -1.275  D15 -1.273 
D6 -1.125  D16 -0.405 
D7 -1.233  D17 -0.693 
D8 -1.031  D18 0.000 
D9 -1.349  D19 1.386 
D10 -1.185  D20 21.203 
 
 
 
 
Figure 1. Scatter plot for the estimated baseline Hazard function. 
 
 
 
Thus to illustrate the output, the hazard probability of first time period is 
calculated and by substituting the values in equation (3) 2 3 20, , , 0t t t   while 
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1 1 2.687
1ˆ1, 0.06
(1 )
t h
e
  

, and to get the hazard probability of the second 
interval 2 1.642
1ˆ 0.16
(1 )
h
e
 

, and so on. The coefficient of the last time period 
had a high negative value, but was actually insignificant in the modeling process. 
This was due to the occurrence of only one event, which had held out till the final 
period in the sample. Also, removing the last interval from the modeling process 
did not induce any significant change to the −2loglikelihood, which was used to 
pick the best model from the four models that were tested. 
Once calculated for all 20 time periods the baseline survival function can be 
calculated using equation (6). Graphical representation of the estimated discrete 
hazard function is shown in Figure 1. And a comparison of the estimated base line 
survival function by the model and the sample survival function is shown in 
Figure 2. 
 
 
 
 
Figure 2. Sample Survival Function and Estimated Baseline Survival. 
 
 
 
In Figure 2 it is shown that the estimated base line model fits the data well. 
This is also supported by the residual analysis from the logistic model used to 
estimate the baseline hazard function. The model residuals came to be 
uncorrelated and with constant variance. Because the distribution of the survival 
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time is skewed, the median survival time is of great interest, as shown in the first 
graph in Figure 2: the estimated median survival time when ( ) 0.5S t  , which is 
equal to 0.5ˆ 48months.t   It is customary to see the discrete survival function as a 
step down function in graphs, but for technical purposes and comparison issues, 
connected lines are used in these Figures rather than a step down function. 
Model 2 
The second model is to see the effect of the covariates on the survival time. The 
first covariate will be age at diagnosis. As discussed in the previous section the 
age of patient at diagnosis is grouped into 9 groups, 10 year interval each. The 
nine groups will be represented by 8 dummy variables with the first age group as 
the base. The parameter estimates are represented in Table 7.  
 
 
Table 7. Parameter estimates for discrete hazard function with Age as covariate 
 
Param. α  Param. α  Param. β 
D1 -3.13  D11 -1.02  age_1 0.28 
D2 -2.04  D12 -1.60  age_2 0.11 
D3 -1.75  D13 -1.28  age_3 0.09 
D4 -1.60  D14 -1.00  age_4 0.41 
D5 -1.62  D15 -1.51  age_5 0.39 
D6 -1.46  D16 -0.63  age_6 0.73 
D7 -1.55  D17 -0.90  age_7 1.00 
D8 -1.33  D18 -0.22  age_8 3.11 
D9 -1.64  D19 1.18    
D10 -1.48  D20 21.11    
 
 
The estimates for the alpha parameters correspond to the time periods. The 
first beta estimate 0.28 corresponds to the second age group (Age 21-30); recall 
that first age group is at base level. For example, the estimated discrete hazard 
probability for the first age group (Age 11-20) of the first time period is 
1 ( 3.13)
1ˆ 0.041887,
(1 )
h
e 
 

 the estimate of the survival probability for the same 
age group in the first time period by equation (4) 1 1
ˆˆ (1 ) 0.958.S h    Similar 
calculations were followed to get the survival for the 20 time periods for each Age 
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group. Figure 3 shows the graph illustration for those survival functions, for each 
age group. 
 
 
 
 
Figure 3. Estimated Survival function plot from Model 2, for different Age groups. 
 
 
 
Looking at the survival plots in Figure 3, the duration time of the melanoma 
cancer is same for patients in the age group 5 and 6. The duration time for the 
second age group is lower than that for Age group 3 and 4, which is closer to the 
duration time of the first age group. For the last age group (Ages 91-100) the 
estimated median survival time corresponds to the first time period, which means 
it is between 1 and 12 months. 
Model 3 
Adding more covariates made the model more significant. Table 8 shows the 
different models that were applied to the data along with the corresponding 
−2loglikelihood and Cox & Snell R-square. The model that best fits the data is the 
last one with the three covariates: Age at diagnosis, Tumor Size and Extension of 
the tumor. 
This model with 0.383 Cox and Snell R-square is considered to be 
significant for the analysis of binary data. This model gave more informative 
estimates about the behavior of the survival time of melanoma cancer patients, 
across the 9 age groups. A plot showing the estimated survival time using the last 
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model based on patients diagnosed with tumor size of group 3 and extension of 
tumor of group 4 (refer to Table 4) is given in Figure 4. 
 
 
Table 8. −2loglikelihood for various models 
 
Model −2loglikehood Cox & Snell R-square 
Base 6088.32 0.369 
Base + Age 6016.71 0.376 
Base + Age + Tumor Size 5981.91 0.379 
Base + Age + Tumor Size + Extension of Tumor 5939.26 0.383 
 
 
 
 
Figure 4. Estimated Survival Function for the different age groups using Model 4. 
 
 
 
Figure 4 represents the estimated survival probability for the 9 age groups: 
A1 for first age group, A2 for second age group, … , A9 for the ninth group. 
According to the model (Model 4), the following results are found for patients 
diagnosed with tumor size between (301mm to 992mm) and at the fourth level of 
tumor extension (No treatment was involved in this model): 
 
 A patient diagnosed at ages 11-20 and 31-50 have the same estimate of 
median survival time less than 5 years. 
 A patient diagnosed at ages 21-30, have an estimate of median 
survival time less than 4 years. 
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 Age group 5 (51-60) and 6 (61-70) have the same estimate of median 
survival time between 3 to 4 years. 
 Figure 4 shows that the maximum estimated survival time for all age 
groups is around 15 years from the time of diagnosis. 
Conclusion 
A statistical model was developed to predict the survival time of localized 
melanoma patients using the discrete survival time method. The discrete survival 
time method gives better results when applied on follow-up data sets. If the 
information about the progress a patient’s tumor thickness and the time of 
treatment patients took is available, the results become more accurate and show 
less prediction error. 
Four different statistical models were developed with a recommended model 
(fourth one) to be the best model for predicting the survival time of a given 
localized melanoma patient. This model is the one that takes into consideration 
the patient’s age at diagnosis, tumor thickness and extension of the tumor. 
In comparison with research by Soong, et al. (2010), the primary melanoma 
site was not considered as one of covariates in the model. Patients were divided 
into 10 groups according to the primary site and model each group separately. 
Results from this study show less error compared with Soong, et al. (2010) 
because the variation due to the difference in the primary site was removed. 
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